Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related ...
The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...
Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Filing of daridorexant in Taiwan planned ...
Idorsia’s Quviviq (daridorexant) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), which means it is likely to be approved for use in around two months.
Idorsia Ltd (SIX: IDIA) today announced the publication of "A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research. The new ...
Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Filing of daridorexant in Taiwan ...
Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...
Nxera Pharma inks agreement with Holling Bio-Pharma to commercialize daridorexant in Taiwan: Tokyo, Japan Monday, March 3, 2025, 16:00 Hrs [IST] Nxera Pharma Co., Ltd. announces t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results